1S90
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outc… Read more
1S90 (1S90) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.050x
Based on the latest financial reports, 1S90 (1S90) has a cash flow conversion efficiency ratio of 0.050x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€2.21 Million) by net assets (€43.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
1S90 - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how 1S90's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
1S90 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 1S90 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TROPHY GAMES DEV. DK-020
F:4H7
|
N/A |
|
Auburn National Bancorporation Inc
NASDAQ:AUBN
|
0.046x |
|
Birlesim Muhendislik Isitma Sogutma Havalandirma Sanayi & Ticaret Sirketi AS
IS:BRLSM
|
-0.179x |
|
Amicogen Inc
KQ:092040
|
-0.022x |
|
MANUKA RESOURCES LTD
F:6M0A
|
N/A |
|
Centaur Media Plc
PINK:CAUUF
|
0.100x |
|
Lihtai Construction Enterprise Co Ltd
TWO:5520
|
0.054x |
|
Bangkok Aviation Fuel Services Public Company Limited
BK:BAFS
|
0.071x |
Annual Cash Flow Conversion Efficiency for 1S90 (2021–2024)
The table below shows the annual cash flow conversion efficiency of 1S90 from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €13.78 Million | €-148.61 Million | -10.781x | -512.09% |
| 2023-12-31 | €-44.86 Million | €-117.35 Million | 2.616x | +112.33% |
| 2022-12-31 | €10.78 Million | €-228.82 Million | -21.220x | -41825.29% |
| 2021-12-31 | €131.51 Million | €6.69 Million | 0.051x | -- |